Database Query Results : Cisplatin, ,

Cisplatin, Cisplatin: Click to Expand ⟱
Features:
Cisplatin is a chemotherapy medication used to treat various types of cancer. It is a platinum-based drug that works by interfering with the DNA of cancer cells, preventing them from reproducing and ultimately leading to cell death.
Scientific Papers found: Click to Expand⟱
1339- 2DG,  Cisplatin,    2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells
- in-vitro, HNSCC, FaDu
ChemoSen↑, ROS↑, GSH↓, other↓,
257- AL,  Cisplatin,    Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors
- in-vitro, NSCLC, A549
ROS↑, HIF-1↓, E-cadherin↑, N-cadherin↓, antiOx↓, Dose↝,
299- ALA,  Cisplatin,  PacT,    Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line
- in-vitro, Ovarian, OVCAR-3
MMP9↓, MMP11↓, MAPK↓,
1235- ALA,  Cisplatin,    α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway
- in-vitro, Nor, HEI-OC1 - ex-vivo, NA, NA
ROS↑, HO-1↓, *toxicity↓, chemoP↑, *ROS↓, *HO-1↑, *SOD1↑, *NRF2↑,
1350- And,  Cisplatin,    Synergistic antitumor effect of Andrographolide and cisplatin through ROS-mediated ER stress and STAT3 inhibition in colon cancer
- in-vitro, Colon, NA
ChemoSen↑, ER Stress↑, STAT3↓, ROS↑,
578- Api,  Cisplatin,    Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis
- in-vitro, Lung, A549 - in-vitro, BC, MCF-7 - in-vitro, CRC, HCT116 - in-vitro, Pca, HeLa - in-vitro, Lung, H1299
p‑P53↑,
581- Api,  Cisplatin,    The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy
- in-vitro, Pca, CD44+
Bcl-2↓, survivin↓, Casp8↑, P53↑, Sharpin↓, APAF1↑, p‑Akt↓, NF-kB↓, P21↑, Cyc↓, CDK2↓, CDK4/6↓, Snail↓, ChemoSen↑,
583- Api,  Cisplatin,    Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study
- in-vitro, Laryn, HEp2
PI3K/Akt↓, GLUT1↓, Akt↓,
584- Api,  Cisplatin,    Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms
- in-vivo, Var, NA
Beclin-1↑, Casp3↑, Casp9↑, JNK↑, Mcl-1↓, Ki-67↓,
564- ART/DHA,  Cisplatin,    Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling
- in-vitro, NA, HN30
JAK2↓, STAT3↓, MMP2↓, MMP9↓, Mcl-1↓, Bcl-xL↓, cycD1/CCND1↓, VEGF↓, TumCCA↑, ChemoSen↑,
1295- AS,  Cisplatin,    Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases
- in-vivo, Laryn, NA
AntiTum↑, Apoptosis↑, Bcl-2↓, BAX↑, Casp3↑, Casp9↑, Bax:Bcl2↑,
1368- Ash,  Cisplatin,    Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’
- in-vitro, Colon, HT-29 - in-vitro, BC, MDA-MB-231
tumCV↓, *toxicity↓, ROS↑, mitResp↓, ChemoSen↑,
2622- Ba,  Cisplatin,  Rad,    Natural Baicalein-Rich Fraction as Radiosensitizer in Combination with Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
RadioS↑,
2627- Ba,  Cisplatin,    Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways
RenoP↑, *iNOS↑, *TNF-α↓, *IL6↓, *NF-kB↓, *MAPK↓, *ERK↓, *JNK↓, *antiOx↑, *NRF2↓, *HO-1↑, *Cyt‑c∅, *Casp3∅, *Casp9∅, *PARP∅,
2628- Ba,  Cisplatin,    Baicalein alleviates cisplatin-induced acute kidney injury by inhibiting ALOX12-dependent ferroptosis
- in-vitro, Nor, HK-2
*RenoP↑, *12LOX↓, *Ferroptosis↓,
730- Bor,  Cisplatin,    The Effect of Boric Acid and Borax on Oxidative Stress, Inflammation, ER Stress and Apoptosis in Cisplatin Toxication and Nephrotoxicity Developing as a Result of Toxication
- in-vivo, NA, NA
*ROS↓, *Inflam↓, RenoP↑,
1450- Bos,  Cisplatin,    3-Acetyl-11-keto-β-boswellic acid (AKBA) induced antiproliferative effect by suppressing Notch signaling pathway and synergistic interaction with cisplatin against prostate cancer cells
- in-vitro, Pca, DU145
ROS↑, MMP↓, Casp↑, Apoptosis↑, Bax:Bcl2↑, TumCCA?, cycD1/CCND1↓, CDK4↓, P21↑, p27↑, NOTCH↓, ChemoSen↑,
1411- CUR,  Cisplatin,    Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects
- Review, Var, NA
ChemoSen↑, *ROS↓, *NF-kB↓, TumCCA↑,
444- CUR,  Cisplatin,    LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells
- vitro+vivo, CRC, HCT8
TumVol↓, Apoptosis↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑PARP1↑, miR-497↑, KCNQ1OT1↓,
949- FIS,  ATAGJ,  Cisplatin,    Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway
- in-vivo, BC, Walker256 - in-vitro, BC, Walker256
Akt↓, Hif1a↓, p‑Akt↓,
1966- GamB,  Cisplatin,    Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
- in-vitro, Lung, A549 - in-vitro, Lung, NCIH1299
TumCCA↑, PARP↑, eff↑, ROS↑, ChemoSen↑,
828- GAR,  Cisplatin,    Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells
- in-vitro, Ovarian, OVCAR-3
tumCV↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, p‑PI3K↓, p‑Akt↓, NF-kB↓,
805- GAR,  Cisplatin,  PacT,    Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells
- Review, NA, NA
ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓,
801- GAR,  Cisplatin,    Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers
- in-vivo, HNSCC, NA
Apoptosis↑, cycD1/CCND1↓, Bcl-2↓, survivin↓, VEGF↓, TumCG↓, Ki-67↓, CD31↓,
1064- LT,  Cisplatin,    Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells
- vitro+vivo, Lung, LNM35 - in-vitro, CRC, HT-29 - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Casp3↑, Casp7↑, HDAC↓,
4781- Lyco,  5-FU,  Chemo,  Cisplatin,    Antioxidant and anti-inflammatory activities of lycopene against 5-fluorouracil-induced cytotoxicity in Caco2 cells
- in-vitro, Colon, Caco-2
chemoP↑, Inflam↓, COX2↓, IL1β↓, IL6↓, TNF-α↓, ROS↑, ChemoSen↑, SOD↓,
4532- MAG,  Cisplatin,    Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation
- in-vivo, Var, NA
cachexia↓, *IGF-1↑, chemoP↑, *M2 MC↑,
4518- MAG,  Cisplatin,    Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells
- in-vitro, GC, MKN45
ChemoSen↑, tumCV↓, BAX↑, Bcl-2↓, P21↑, P53↑, MMP9↓,
2043- PB,  Cisplatin,    Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
- in-vitro, HNSCC, UM-SCC-1
ChemoSen↑, eff↑, HDAC↓, BRCA1↓, RadioS↑,
4920- PEITC,  Cisplatin,    PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p
- vitro+vivo, NSCLC, A549
TumCG↓, ChemoSen↑, cMyc↓, PI3K↓, Akt↓, mTOR↓, BioAv↝, tumCV↓, ChemoSen↑,
4965- PSO,  Cisplatin,    The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis
- vitro+vivo, GC, HGC27 - vitro+vivo, GC, MKN45
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, *toxicity↓, eff↑, Ferroptosis↑, ACSL4↑, GPx4↓, ChemoSen↑, chemoP↑, AntiTum↑, Sepsis↓,
4704- PTS,  Cisplatin,    Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS
- in-vitro, Bladder, NA
PI3K↓, mTOR↓, P70S6K↓, MEK↑, ERK↑, ChemoSen↑, TumAuto↑,
2184- SK,  Cisplatin,    PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
- in-vitro, CRC, T24
PKM2↓, ChemoSen↑, Necroptosis↑,
2182- SK,  Cisplatin,    Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway
- in-vitro, Lung, A549 - in-vitro, Lung, PC9 - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, PKM2↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, TumVol↓, TumW↓, GLUT1↓,
2008- SK,  Cisplatin,    Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
ChemoSen↑, selectivity↑, i-ROS↑, DNAdam↑, MMP↓, TumCCA↑, eff↓, *toxicity↓,
322- SNP,  Cisplatin,    Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, OVCAR-3
ROS↑, DNAdam↑, GSH/GSSG↓,
2133- TQ,  CUR,  Cisplatin,    Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling
- in-vitro, Nor, HEK293 - in-vivo, NA, NA
*creat↓, *TNF-α↓, *IL6↓, *MRP↓, *GFR↑, *mt-ATPase↑, *p‑Akt↑, *NRF2↑, *HO-1↑, *Casp3↓, *NF-kB↓, *RenoP↑,
2116- TQ,  Cisplatin,    Oral administration of Nigella sativa oil ameliorates the effect of cisplatin on membrane enzymes, carbohydrate metabolism and oxidative damage in rat liver
- in-vivo, Nor, NA
*hepatoP↑, *antiOx↑, *ROS↓, ALAT↓, AST↓,
2099- TQ,  Cisplatin,    Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
- in-vitro, Lung, H460 - in-vitro, Lung, H146 - in-vivo, NA, NA
ChemoSen↑, TumCP↓, tumCV↓, Apoptosis↑, NF-kB↓,
4887- ZER,  Rad,  Cisplatin,    Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma
- in-vitro, HNSCC, CAL27
Apoptosis↑, ChemoSen↑, RadioS↑, tumCV↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 40

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   GSH/GSSG↓, 1,   HO-1↓, 1,   ROS↑, 10,   i-ROS↑, 1,   SOD↓, 1,  

Mitochondria & Bioenergetics ⓘ

MEK↑, 1,   mitResp↓, 1,   MMP↓, 3,  

Core Metabolism/Glycolysis ⓘ

ACSL4↑, 1,   ALAT↓, 1,   cMyc↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   lactateProd↓, 1,   PI3K/Akt↓, 2,   PKM2↓, 2,  

Cell Death ⓘ

Akt↓, 3,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 7,   BAX↑, 5,   Bax:Bcl2↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 1,   Casp↑, 1,   Casp3↑, 4,   cl‑Casp3↑, 2,   Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 3,   Cyt‑c↑, 1,   Ferroptosis↑, 1,   JNK↑, 1,   MAPK↓, 1,   Mcl-1↓, 2,   miR-497↑, 1,   Necroptosis↑, 1,   p27↑, 1,   survivin↓, 2,  

Transcription & Epigenetics ⓘ

HATs↓, 1,   KCNQ1OT1↓, 1,   other↓, 1,   tumCV↓, 7,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

BRCA1↓, 1,   DNAdam↑, 2,   P53↑, 2,   p‑P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 1,   cl‑PARP1↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   Cyc↓, 1,   cycD1/CCND1↓, 3,   P21↑, 3,   TumCCA?, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   ERK↑, 1,   HDAC↓, 2,   Let-7↑, 1,   mTOR↓, 2,   NOTCH↓, 1,   NOTCH1↓, 1,   P70S6K↓, 1,   PI3K↓, 2,   p‑PI3K↓, 1,   STAT3↓, 3,   TumCG↓, 3,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

CD31↓, 1,   CDK4/6↓, 1,   E-cadherin↑, 2,   Ki-67↓, 2,   MMP11↓, 1,   MMP2↓, 1,   MMP9↓, 4,   N-cadherin↓, 1,   Sharpin↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 3,   Vim↓, 1,   Zeb1↓, 1,   ZEB2↓, 1,  

Angiogenesis & Vasculature ⓘ

HIF-1↓, 1,   Hif1a↓, 1,   VEGF↓, 3,  

Barriers & Transport ⓘ

GLUT1↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1β↓, 1,   IL6↓, 2,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 4,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   ChemoSen↑, 21,   Dose↝, 1,   eff↓, 1,   eff↑, 3,   RadioS↑, 3,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BRCA1↓, 1,   IL6↓, 2,   Ki-67↓, 2,  

Functional Outcomes ⓘ

AntiTum↑, 2,   cachexia↓, 1,   chemoP↑, 4,   RenoP↑, 2,   TumVol↓, 2,   TumW↓, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 124

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Ferroptosis↓, 1,   HO-1↑, 3,   NRF2↓, 1,   NRF2↑, 2,   ROS↓, 4,   SOD1↑, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,  

Cell Death ⓘ

p‑Akt↑, 1,   Casp3↓, 1,   Casp3∅, 1,   Casp9∅, 1,   Cyt‑c∅, 1,   Ferroptosis↓, 1,   iNOS↑, 1,   JNK↓, 1,   MAPK↓, 1,  

DNA Damage & Repair ⓘ

PARP∅, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   IGF-1↑, 1,  

Migration ⓘ

mt-ATPase↑, 1,  

Barriers & Transport ⓘ

MRP↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL6↓, 2,   Inflam↓, 1,   M2 MC↑, 1,   NF-kB↓, 3,   TNF-α↓, 2,  

Clinical Biomarkers ⓘ

creat↓, 1,   IL6↓, 2,  

Functional Outcomes ⓘ

GFR↑, 1,   hepatoP↑, 1,   RenoP↑, 2,   toxicity↓, 4,  
Total Targets: 33

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:197  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page